
Valneva's chikungunya vaccine IXCHIQ® shows 94% antibody persistence five years after one dose
Valneva announced that 94% of participants maintained a strong antibody response five years after a single dose of its chikungunya vaccine IXCHIQ®. The vaccine showed durable immunity across all age groups, including adults over 65, supporting its po...





